InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field

Uniting FDA-authorized trials, ketamine and Spravato therapy, therapist training, and community education under one roof, InnerMost brings a vital new resource, contributing to the field globally

NEW YORK, NY / ACCESS Newswire / November 21, 2025 / InnerMost PBC, New York City's new psychedelic-assisted therapy center dedicated to accessible care, practitioner training, FDA-authorized clinical trials, and community building, is officially open.

A public benefit corporation, InnerMost provides accessible ketamine and Spravato therapy, is an FDA-trial site that trains psychedelic-assisted therapists, and builds community amongst clinicians in this paradigm-shifting field.

With mental health needs at an all-time high, and uncertainty across politics and research, its launch introduces a hub for evidence-based psychedelic care-supporting New Yorkers while advancing access and progress globally. New hope emerges as the mainstream embraces new evidence-based approaches that expand what's possible in mental health care.

Leading conversations about psychedelic therapy's past, present and future is Casey Paleos, MD, (CV) Co-Founder & Chief Medical Officer, board-certified psychiatrist and researcher with 15+ years in psychedelic-assisted therapy. As figures like Rick Doblin pass the baton, they sing praises about his body of work and vision:

  • Principal Investigator, MAPS MDMA therapy for PTSD Studies

  • Therapist, NYU Psilocybin Cancer Anxiety Study

  • Co-Founder, Nautilus Sanctuary

  • Founding Board Member, International Alliance of MDMA Practitioners

  • Presenter, "Understanding Ketamine" Workshop, Psychotherapy Networker conference, Washington, D.C.

  • Co-Author of "Inner-Directed Therapy in MDMA-Assisted Psychotherapy," newly released commentary on the MDMA debate in the American Journal of Psychiatry

WHY INNERMOST IS DIFFERENT:

  • Research:FDA-authorized clinical trial site, including ongoing MDMA research and more TBA.

  • Treatment: Integration of psychotherapy with ketamine, Spravato, and future integrative mental health modalities.

  • Training: Practicum training, mentorship and clinical supervision.

  • Education & Community: Public programming, podcasts, panels, and partnerships.

  • Accessibility: Public benefit corporation whose mission is to eliminate socioeconomic barriers to accessing psychedelic therapies.

VISUALS:

  • First look at InnerMost's space and design.

  • Interviews with Dr. Paleos and team.

  • Photo and video opportunities.

Now open to the public by appointment at innermost.one, media are invited to schedule private tours of InnerMost.

MEDIA CONTACT: Marissa Feinberg | marissa@triplebottomwhy.com | 917-494-5041

SOURCE: InnerMost



View the original press release on ACCESS Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.61
+0.39 (0.17%)
AAPL  278.00
-0.85 (-0.30%)
AMD  217.29
-0.24 (-0.11%)
BAC  53.58
-0.07 (-0.13%)
GOOG  316.24
-3.88 (-1.21%)
META  641.08
-6.87 (-1.06%)
MSFT  487.82
-4.19 (-0.85%)
NVDA  178.85
+1.85 (1.05%)
ORCL  202.17
+0.22 (0.11%)
TSLA  427.07
-3.10 (-0.72%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gift this article